<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045525</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2009-A00831-56</org_study_id>
    <secondary_id>PHRC / 09-02</secondary_id>
    <nct_id>NCT01045525</nct_id>
  </id_info>
  <brief_title>Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis</brief_title>
  <acronym>SAIGNEES</acronym>
  <official_title>Prospective Randomized Study Comparing the Effect of Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only on Glycemia in Patients With Dysmetabolic Liversiderosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance-associated hepatic iron overload (IR-HIO), also defined as dysmetabolic
      iron overload syndrome or dysmetabolic liversiderosis, is a common cause or iron overload in
      France, mainly in middle-age patients with increased serum ferritin levels associated with
      normal serum transferrin saturation, and normal serum iron concentration in the absence of
      other known cause of increased serum ferritin levels.

      Treatment includes a combination of dietary measures and physical activity to correct
      metabolic disorders. Phlebotomies seem to be beneficial when serum ferritin level is high.

      This study aims at comparing the effect of iron depletion (by phlebotomy) plus lifestyle and
      diet advices versus lifestyle and diet advices alone on blood glucose level and insulin
      sensitivity in subjects with IR-HIO in order to assess the benefits of phlebotomies on the
      reduction of risk of diabetes and cardiovascular associated complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non applicable
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting blood glycemia (T0 of Oral Glucose Tolerance Test)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Body mass index &gt; 25 kg/m²</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of systolic blood pressure ≥ 130mmHg or diastolic blood pressure ≥ 85 mmHg or antihypertensive treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of abdominal obesity (waist measurement ≥ 94 cm for men and ≥ 80 cm for women)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fasting triglyceridemia ≥ 1.7 mmol/L or triglyceride-lowering treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fasting HDL cholesterol &lt; 1.03 mmol/L for men and &lt; 1.29 mmol/L for women or HDL cholesterol-elevating treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fasting glycemia ≥ 5.6 mmol/L</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life estimated with SF36 form and tolerance to treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinoresistance indexes calculated at T0 and T30 min of Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers: CRP, hyaluronic acid, fibrometer</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial deformation</measure>
    <time_frame>12 months</time_frame>
    <description>Two dimensional (2D) speckle tracking echocardiography (STE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Phlebotomy + lifestyle and diet advices</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle and diet advices</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>From 300 to 400mL for women; From 350 to 450mL for men</description>
    <arm_group_label>Phlebotomy + lifestyle and diet advices</arm_group_label>
    <other_name>Non applicable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle and diet advices</intervention_name>
    <description>2 Booklets with Dietary and physical activity advices</description>
    <arm_group_label>Lifestyle and diet advices</arm_group_label>
    <other_name>Non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18

          -  Signed written informed consent

          -  Ferritin ≥ 450 µg/L and ≤ 1500 µg/L

          -  Hepatic iron overload proved by MRI or histological biochemical measurement (Iron
             hepatic concentration ≥ 50 μmol/g)

          -  At least one of the following criteria :

               -  Body mass index &gt; 25 kg/m²

               -  Systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg or
                  antihypertensive treatment

               -  Abdominal obesity (waist measurement ≥ 94 cm for men and ≥ 80 cm for women)

               -  Fasting triglyceridemia ≥ 1.7 mmol/L or triglyceride-lowering treatment

               -  Fasting HDL cholesterol &lt; 1.03 mmol/L for men and &lt; 1.29 mmol/L for women or HDL
                  cholesterol-elevating treatment

               -  Fasting blood glycemia ≥ 5.6 mmol/L

        Exclusion Criteria:

          -  Subjects deprived of their liberty by judicial or administrative decision

          -  Pregnant women

          -  Other causes of increased serum ferritin levels:

               -  Inflammatory syndrome (CRP &gt;10 mg/L) or inflammatory, immune or malignant
                  diseases

               -  Hyper-hemolysis

               -  Alcohol consumption more than 210 g for men and 140 g for women per week within
                  the year before inclusion

               -  Haemochromatosis established by the C282Y homozygous genotype

               -  Chronic hepatic cytolysis due to : viral infection (HBV, HCV), alcohol,
                  hyperthyroid disease, celiac disease, drug or immune hepatitis

               -  Increased serum ferritin levels - cataract syndrome (familial cataract or
                  personal history of cataract before 50 years of age)

               -  Low ceruloplasmin level

               -  Porphyria (cutaneous signs)

          -  Contraindication of phlebotomy

               -  Haemoglobin &lt;13 g/dL for men and &lt;12g/dL for women (threshold established by the
                  French Blood Agency)

               -  Congestive heart failure or coronary heart disease

               -  Hepatic failure (TP&lt;60%), renal failure (GFR &lt;50mL/min) or respiratory
                  insufficiency (chronic dyspnea)

               -  Poor venous system

          -  Fasting blood glycemia &gt; 7 mmol/L or type 1 or type 2 diabetes, treated or not

          -  Use of drugs known to have anti-steatotic effects : metformin, thiazolidinedione
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice LAINE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BELLISSANT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Roche Sur Yon Hospital</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lorient Hospital</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des maladies du foie - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Malo Hospital</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phlebotomy</keyword>
  <keyword>Dysmetabolic liversiderosis</keyword>
  <keyword>Hepatic Iron overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

